During the past decade, Genge Partners, Inc. conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Genge Partners, Inc." #1 collaborator was "Novartis Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Genge Partners, Inc." are "Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation" (1 trials) and "Multiple Sclerosis" (1 trials). Many other conditions were trialed in "Genge Partners, Inc." in a lesser frequency.

Most popular intervention types in "Genge Partners, Inc." are "Device" (1 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "BIIB067 (Tofersen)" (1 trials), "Eye-Tracking" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Genge Partners, Inc." are 2 trials for "All" genders.

Currently, there are NaN active trials in "Genge Partners, Inc.". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Genge Partners, Inc., undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Genge Partners, Inc., 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".